

Please type a plus sign (+) inside this box →

PTO/SB/08A (10-96)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

~~RECEIVED~~

A circular stamp with "U.S. PATENT & TRADEMARK OFFICE" around the perimeter. The center contains "OCT 2 2002" and "JCA2".

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 3

Complete if Known

OCT 05 2009

TECH CENTER 1600/2900

Application Number	09/101,413
Filing Date	January 17, 1997
First Named Inventor	Hans Josef Stauss
Group Art Unit	1644
Examiner Name	Ewoldt, G.R.
Attorney Docket Number	RPMS 102

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
<i>AE</i>	WO	91/07509	A1	05-30-1991	Massachusetts Inst. of Tech.			
<i>J</i>	WO	95/29995	A1	11-19-1995	The Wistar Inst. of Anatomy and Biology			
<i>J</i>	WO	97/26328	A1	07-24-1997	RPMS Technology Ltd.			
	WO	00/06602	A1	02-10-2000	H. Sugiyama			
<i>SP</i>	WO	00/18795	A2	04-06-2000	Corixa Corp.			
<i>SP</i>	JP	10 218093		07-31-1999	H. Sugiyama			

Examinee Signature	<u>Eve H</u>	Date Considered	10/17/02
-----------------------	--------------	-----------------	----------

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language translation is available.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patent, Washington, DC 20231.

ATI 1 #545683 v1


RPMS 102
078230/00002

Please type a plus sign (+) inside this box →

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 3

RECEIVED

Complete If Known

Application Number	09/101,413	OCT 05 2002
Filing Date	January 17, 1997	
First Named Inventor	Hans Josef Staus	
Group Art Unit	1644	
Examiner Name	Ewoldt, G.R.	
Attorney Docket Number	RPMS 102	

TECH CENTER 1600/2900

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
<i>Ew</i>		AL-OBEIDI, et al., "Peptide and peptidomimetic libraries," <i>Molecular Biotechnology</i> 9:205-223 (1998).	
		BEELEY, "Peptidomimetics and small-molecule drug design: towards improved bioavailability and <i>in vivo</i> stability," <i>TIBTECH</i> 12:213-216 (1994).	
		BLUYSEN, et al., "The interferon-stimulated gene 54 K promoter contains two adjacent functional interferon-stimulated response elements of different strength, which act synergistically for maximal interferon-alpha inducibility," <i>Eur. J. Biochem</i> 220: 395-402 (1994)	
		BOTTGER, et al., "Molecular characterization of the hdm2-p53 interaction," <i>J Mol Biol</i> 269:744-756 (1997).	
		BUCKLER, et al., "Isolation, Characterization, and Expression of the Murine Wilms' Tumor Gene (WT1) During Kidney Development," <i>Molecular and Cellular Biology</i> 11(3): 1707-1712 (1991).	
		CROSSLEY & ORKIN, "Phosphorylation of the Erythroid Transcription Factor GATA-1," <i>J Bio Chem</i> 269:16589-96 (1994).	
		GAIGER, et al., "Immunity to WT1 in the animal model and in patients with acute myeloid leukemia," <i>Blood</i> 96(4):1480-89 (2000).	
		GAO, et al., "Selective elimination of leukemic CD34+ progenitor cells by cytotoxic T lymphocytes specif for WT1," <i>Blood</i> 95:2198-2203 (2000).	
		JANEWAY, et al., <i>Immunobiology</i> 4 th Edition (Austin et al., eds.), pages 121, 551, 569, Figures 4.3, 4.5 and 4.7, Garland Press 1999	
<i>Ew</i>		KIEBER-EMMONS, et al., "Therapeutic peptides and peptidomimetics," <i>Curr Opinion Biotechnol</i> 8:436-441 (1997).	

Examiner's Signature *Ewoldt* Date Considered *10/17/02*

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+



Please type a plus sign (+) inside this box →

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

Complete if Known

RECEIVED

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 3

Application Number

09/101,413

OCT 05 2002

TECH CENTER 1600/2900

Filing Date	January 17, 1997
First Named Inventor	Hans Josef Stauss
Group Art Unit	1644
Examiner Name	Ewoldt, G.R.

Attorney Docket Number

RPMS 102

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
<i>bfg</i>		MEZIERE, et al., "In vivo helper cell response to retro-inverso peptidomimetics," <i>Journal of Immunology</i> 159:3230-37 (1997).	
		MURALI & GREENE, "Structure-based design of immunologically active therapeutic peptides," <i>Immunologic Research</i> 17(1&2):163-169 (1998).	
		NAKANISHI, et al., "Peptidomimetics of the immunoglobulin supergene family – a review," <i>Gene</i> 137:51-56 (1993).	
		OHMINAMI, et al., "HLA class I-restricted lysis of leukemia cells by a CD8+ cytotoxic T-lymphocyte clone specific for WT1 peptide," <i>Blood</i> 95:286-93 (2000).	
		OKA, et al., "Cancer immunotherapy targeting Wilms' Tumor Gene WT1 product," <i>J Immunol</i> 164:1873-80 (2000).	
		OKA, et al., "Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms tumor (WT1) product," <i>Immunogenetics</i> 51:99-107 (2000).	
		SADOVNIKOVA & STAUSS, "Peptide-specific cytotoxic T lymphocytes restricted by nonself major histocompatibility complex class I molecules: reagents for tumor immunotherapy," <i>Proc Natl Acad Sci USA</i> 93:13114-13118 (1996).	
		SEMBA, et al., "cDNA cloning and its pronephros-specific expression of the Wilms' tumor suppressor gene, WT1, from <i>Xenopus laevis</i> ," <i>Gene</i> 175: 167-172 (1996).	
<i>ewoldt</i>		SHARMA, et al., "Molecular Cloning of Rat Wilm's Tumor Complementary DNA and a Study of Messenger RNA Expression in the Urogenital System and the Brain," <i>Cancer Research</i> 52: 6407-6412 (1992).	

Examiner's Signature *Ewoldt* Date Considered 10/17/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

Complete if Known

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

MAY 17 1999

PATENT & TRADEMARK OFFICE USCG

Sheet

1 of

3

Application Number 09/101,413

Filing Date August 7, 1998
First Named Inventor Hans Josef Stauss
Group Art Unit 1602
Examiner Name Kefy
Attorney Docket Number RPMS 102

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	US Patent Document	Name of Patentee or Applicant of Cited Document	Date of Cited Document MM-DD-YYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)		
JKY		4,844,893	Honsik, et al.	07-04-1989	
JKY		4,690,915	Rosenberg	09-01-1987	

OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T ²
JKY		DAHL, et al., "Normal Self Proteins as Targets for Tumour Specific Cytotoxic Lymphocytes (CTL)," 9 th International Congress of Immunology, San Francisco, CA, USA 607 (1995).	
		DAHL, et al., "A synthetic peptide derived from the tumor-associated protein mdm2 can stimulate autoreactive, high avidity cytotoxic T lymphocytes that recognize naturally processed protein," J Immunol 157(1):239-46 (1996).	
		HILL, et al., "Class I major histocompatibility complex-restricted cytotoxic T lymphocytes specific for Epstein-Barr virus (EBV)-transformed B lymphoblastoid cell lines against which they were raised," J Exp Med 181(6):2221-8 (1995).	
		HSU, et al., "Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells," Nat Med 2(1):52-8 (1996).	
		INOUE, et al., "Long-term follow-up of minimal residual disease in leukemia patients by monitoring WT1 (Wilms tumor gene) expression levels," Blood 88(6):2267-78 (1996).	
		JEROME, et al., "Tumor-specific cytotoxic T cell clones from patients with breast and pancreatic adenocarcinoma recognize EBV-immortalized B cells transfected with polymorphic epithelial mucin complementary DNA," J Immunol 151(3):1654-62 (1993).	
		KAWAKAMI, et al., "Shared human melanoma antigens. Recognition by tumor-infiltrating lymphocytes in HLA-A2.1-transfected melanomas," J Immunol 148(2):638-43 (1992).	

Examinee Signature	M.T. [Signature]	4/17/04	Date Considered	1-12-2004
--------------------	------------------	---------	-----------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patent, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/101,413
		MAY 17 1999 PATENT & TRADEMARK OFFICE U.S. DEPARTMENT OF COMMERCE	
		Filing Date	August 7, 1998
		First Named Inventor	Hans Josef Stauss
		Group Art Unit	1644
		Examiner Name	
Sheet	2	of	3
Attorney Docket Number RPMS 102			

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T ²
		KWAK, et al., "Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor," <i>Lancet</i> 345(8956):1016-20 (1995).	
		LU, et al., "Improved Synthesis of 4-Alkoxybenzyl Alcohol Resin," <i>J. Org. Chem.</i> 46: 3433-3436 (1981).	
		MELIEF, Prospects of T-cell immunotherapy for cancer by peptide vaccination," <i>Semin Hematol</i> 30(3 Suppl 3):32-3 (1993).	
		MENNSEN, et al., "Presence of Wilms' tumor gene (wt1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias," <i>Leukemia</i> 9(6):1060-7 (1995).	
		MURPHY, et al., "Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen," <i>Prostate</i> 29(6):371-80 (1996).	
		PEOPLES, et al., "Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide," <i>Proc Natl Acad Sci U S A</i> 92(2):432-6 (1995).	
		PLEBANSKI, et al., "Induction of peptide-specific primary cytotoxic T lymphocyte responses from human peripheral blood," <i>Eur J Immunol</i> 25(6):1783-7 (1995).	
		RODECK, et al., "Expression of the wt1 Wilms' tumor gene by normal and malignant human melanocytes," <i>Int J Cancer</i> 59(1):78-82 (1994).	
		SHIMAMOTO, et al., "The expression pattern of erythrocyte/megakaryocyte-related transcription factors GATA-1 and the stem cell leukemia gene correlates with hematopoietic differentiation and is associated with outcome of acute myeloid leukemia," <i>Blood</i> 86(8):3173-80 (1995).	
		TAMAKI, et al., "Increased expression of the Wilms tumor gene (WT1) at relapse in acute leukemia," <i>Blood</i> 88(11):4396-8 (1996).	

Examiner's Signature	M.T. [Signature] 4/17/98	Date Considered	1-12-2000
----------------------	--------------------------	-----------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for Form 1449A/PTO		U.S. PATENT & TRADEMARK OFFICE	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			
(use as many sheets as necessary)			
		Complete if Known	
		Application Number	09/101,413
		Filing Date	August 7, 1998
		First Named Inventor	Hans Josef Strauss
		Group Art Unit	3640-1644
		Examiner Name	
Sheet	3	of	3
		Attorney Docket Number	RPMS 102

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T ²
<i>[Signature]</i>		VIEL, et al., "Molecular mechanisms possibly affecting WT1 function in human ovarian tumors," <i>Int J Cancer</i> 57(4):515-21 (1994).	

Examiner's Signature	M T W R F S U Sept 4/17/04	Date Considered	1-12-2005
----------------------	-------------------------------	-----------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.